Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences (RCUS)
NYSE:RCUS
RCUS Stock Chart & Stats
$21.79
-$0.04(-0.26%)
At close: 4:00 PM EST
$21.79
-$0.04(-0.26%)
Day’s Range― - ―
52-Week Range$6.50 - $26.40
Previous CloseN/A
Volume107.84K
Average Volume (3M)1.30M
Market Cap
$2.68B
Enterprise Value$2.07B
Total Cash (Recent Filing)$831.00M
Total Debt (Recent Filing)$111.00M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Feb 25, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding123,728,540
10 Day Avg. Volume885,838
30 Day Avg. Volume1,297,621
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.77
Price to Sales (P/S)5.20
P/FCF Ratio-7.62
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue8.61
Enterprise Value/Gross Profit8.68
Enterprise Value/Ebitda-6.40
Forecast
1Y Price Target
$30.00Price Target Upside37.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.86
Revenue Forecast (FY)$123.00M
Bulls Say, Bears Say
Bulls Say
Clinical CatalystsMultiple casdatifan monotherapy and combination clinical readouts are positioned to materially influence the stock outlook if they demonstrate positive efficacy and safety results.
Financial RunwayA cash and investment position near $1 billion provides runway into 2028 to advance casdatifan through key clinical stages and fund planned operations.
Phase 2 Efficacy ReadthroughPhase 2 EDGE-Gastric results showing median overall survival roughly double the standard of care suggest robust efficacy that could support broader development of HIF2α inhibitors.
Bears Say
Concentration RiskGreater company reliance on a single program, casdatifan, increases exposure to binary clinical outcomes and the expectation of only incremental data limits catalyst-driven upside.
Revenue OutlookRemoval of projected sales for the discontinued gastric cancer program reduces expected future revenue contributions and trims upside in financial models.
Trial DiscontinuationDiscontinuation of the Phase 3 STAR-221 study for domvanalimab plus zimberelimab removes a near-term value driver and raises questions about the TIGIT program's viability.
Arcus Biosciences News
RCUS FAQ
What was Arcus Biosciences’s price range in the past 12 months?
Arcus Biosciences lowest stock price was $6.50 and its highest was $26.40 in the past 12 months.
What is Arcus Biosciences’s market cap?
Arcus Biosciences’s market cap is $2.68B.
When is Arcus Biosciences’s upcoming earnings report date?
Arcus Biosciences’s upcoming earnings report date is Feb 25, 2026 which is in 25 days.
How were Arcus Biosciences’s earnings last quarter?
Arcus Biosciences released its earnings results on Oct 28, 2025. The company reported -$1.27 earnings per share for the quarter, beating the consensus estimate of -$1.31 by $0.04.
Is Arcus Biosciences overvalued?
According to Wall Street analysts Arcus Biosciences’s price is currently Undervalued.
Does Arcus Biosciences pay dividends?
Arcus Biosciences does not currently pay dividends.
What is Arcus Biosciences’s EPS estimate?
Arcus Biosciences’s EPS estimate is -1.11.
How many shares outstanding does Arcus Biosciences have?
Arcus Biosciences has 123,728,540 shares outstanding.
What happened to Arcus Biosciences’s price movement after its last earnings report?
Arcus Biosciences reported an EPS of -$1.27 in its last earnings report, beating expectations of -$1.31. Following the earnings report the stock price went up 2.062%.
Which hedge fund is a major shareholder of Arcus Biosciences?
Currently, no hedge funds are holding shares in RCUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (37.68% Upside)
$30.00 (37.68% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 410.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.48%
12-Months-Change
Fundamentals
Return on Equity
-68.13%
Trailing 12-Months
Asset Growth
-22.20%
Trailing 12-Months
Company Description
Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
RCUS Stock 12 Month Forecast
Average Price Target
$30.00
▲(37.68% Upside)
Technical Analysis
Ownership Overview
29.65% Insiders
10.53% Mutual Funds
42.09% Other Institutional Investors
1.15% Public Companies and
Individual Investors